Julie Kim
CEO-elect, Interim Head, Global Portfolio Division
Replay available
Takeda Pharmaceutical Company Limited (TAK) Q2 2025 Earnings Call
Takeda Pharmaceutical Company Limited (NYSE: TAK) Q2 2025 earnings conference call, held 2025-10-30. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Steve Barker
Analyst, Jefferies
Giles Patford
President, Plasma Derived Therapy Business Unit
Tony Ren
Analyst, Macquarie
Christophe Weber
President and CEO
Mirano Furuta
Chief Financial Officer
Andy Phuong
President, R&D
Teresa Vittetti
Head of Business Development & Partnerships
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Takeda Pharmaceutical Co. Ltd..
Replay transcript excerpt
WEBVTT 00:00:00.031 -- 00:00:05.641 Thank you very much for taking time out of your very busy schedule to join Takeda's 00:00:05.641 -- 00:00:08.105 FY25 Q2 earnings announcement. 00:00:08.105 -- 00:00:09.728 On 00:00:09.728 -- 00:00:13.093 the MC today, head of IR, my name is O'Reilly. 00:00:13.093 -- 00:00:15.574 Thank you for this opportunity. 00:00:15.758 -- 00:00:18.964 Allow me to explain about the language setting first. 00:00:18.964 -- 00:00:24.454 Please find the language selection button at the bottom of your Zoom window. 00:00:24.454 -- 00:00:27.098 If you wish to listen in Japanese, please select Japanese. 00:00:27.098 -- 00:00:30.024 If you wish to listen in English, please select English. 00:00:30.024 -- 00:00:35.401 Or if you prefer the original voice, please keep this choice off. 00:00:35.401 -- 00:00:37.401 Before 00:00:37.643 -- 00:00:39.265 starting, 00:00:39.265 -- 00:00:42.668 I'd like to remind everyone that we'll be discussing forward-looking statements within 00:00:42.668 -- 00:00:47.032 the meaning of the Private Securities Litigation Reforms Act of 1995. 00:00:47.032 -- 00:00:49.032 Actual 00:00:50.034 -- 00:00:54.618 results may differ materially from those discussed today. 00:00:54.618 -- 00:00:59.243 The factors that could cause our actual results to differ materially are discussed in 00:00:59.243 -- 00:01:04.446 our most recent Form 20F and in our other SEC filings. 00:01:05.168 -- 00:01:07.168 It 00:01:08.953 -- 00:01:14.480 is also referred to the important notice on page 2 of the presentation regarding forward-looking 00:01:14.480 -- 00:01:19.207 statements on our non-IFRS financial measures, which will also be discussed during this 00:01:19.207 -- 00:01:24.494 call. Definitions of our non-IFRS measures and reconciliations with the co...